DIFFERENTIAL IRON STATUS AND TRAFFICKING IN BLOOD AND PLACENTA OF ANEMIC AND NON-ANEMIC PRIMIGRAVIDA SUPPLEMENTED WITH DAILY AND WEEKLY IRON FOLIC ACID TABLETS
(Abstract release date: 05/19/16)
EHA Library. Shankar H. 06/09/16; 135031; PB2131
Mr. Hari Shankar
Contributions
Contributions
Abstract
Abstract: PB2131
Type: Publication Only
Background
Iron deficiency (ID) globally impact billions of people; mostly pregnant women. Anemia during pregnancy is mainly associated with ID; and prophylaxis includes daily supplementation of iron folic acid (IFA) tablets. During pregnancy, increased foetal iron demand leads to fluctuations in body iron reserves; thus supplemental iron is recommended to meet the iron demand. The effectiveness of weekly IFA supplementation in comparison to daily IFA intake during pregnancy is still shadowy, as the available data from well-defined clinical trials is inconsistent. The amount of quantifiable iron circulating in blood and stored in placenta, in both the supplementation schemes and their correlation with pregnancy outcomes is pre-requisite to reach any firm conclusion. Owing to this, the present study was conducted to providing better understanding of hemodynamics and molecular mechanism in human placental iron transfer.
Aims
To investigate the iron dynamics in anemic and healthy pregnant women supplemented with daily and weekly IFA supplementation and its relation with clinical outcome.
Methods
The subjects include non-anemic primigravida (NAP) (Hemoglobin (Hb) > 11 g/ dl, N= 60) and anemic primigravida (AP) (8.0 < Hb < 11 g/ dl, N=60) were followed across pregnancy at three time-points i.e. baseline (13-16 weeks of gestation), after three months (25-28 weeks) and 6 weeks postpartum. The subjects (NAP and AP) were randomly allocated to daily dose comprised 100 mg iron and 500 μg folic acid tablets and weekly dose contained two IFA tablets/ week till six weeks postpartum. Corresponding changes in hematological markers, iron status indicators viz. ferritin, iron and soluble transferrin receptor (sTfR) in blood and placental ferritin expression was studied. Birth outcome, gestational length, infant weight and placental weight were recorded. The statistical significance level (p <0.05) between the groups were assessed by applying unpaired t-test using SPSS (version 20.0).
Results
Weekly IFA supplementation for three months has significantly altered the Hb, hematocrit and red blood cell (RBC) count (p<0.05) and increased the level of serum sTfR (p<0.002) at postpartum in AP. After three months of supplementation, serum iron and sTfR were significantly different (p<0.01) between the two supplemental groups in NAP; whereas, serum ferritin (p<0.001) was significantly high at postpartum in daily IFA group of NAP. Placental ferritin expression was increased in NAP supplemented with daily IFA in comparison to weekly IFA. The placentas obtained from AP supplemented with weekly IFA showed significantly low ferritin (p<0.05) expression when compared with daily IFA supplementation. However, birth outcome, infant weight, gestational length and placental weight were comparable in both the supplementation groups.
Conclusion
The placental ferritin expression and its serum level showed similar trend among anemic and non-anemic primigravidas supplemented with daily and weekly IFA tablets. Although, significantly lower placental ferritin was observed in AP supplemented with weekly IFA tablets; but there was not any difference in birth outcome, infant weight or gestational length between two supplementation groups. The modulation in iron transporter expression may be involved in anemic placentas to flux iron for developing fetus, thereby maintaining the healthy pregnancy. The results of this study revealed that blood iron status/ hematological markers may be helpful to assess the optimum amount of supplemental iron required during pregnancy.
Session topic: E-poster
Keyword(s): Iron deficiency anemia, Iron transport, Pregnancy
Type: Publication Only
Background
Iron deficiency (ID) globally impact billions of people; mostly pregnant women. Anemia during pregnancy is mainly associated with ID; and prophylaxis includes daily supplementation of iron folic acid (IFA) tablets. During pregnancy, increased foetal iron demand leads to fluctuations in body iron reserves; thus supplemental iron is recommended to meet the iron demand. The effectiveness of weekly IFA supplementation in comparison to daily IFA intake during pregnancy is still shadowy, as the available data from well-defined clinical trials is inconsistent. The amount of quantifiable iron circulating in blood and stored in placenta, in both the supplementation schemes and their correlation with pregnancy outcomes is pre-requisite to reach any firm conclusion. Owing to this, the present study was conducted to providing better understanding of hemodynamics and molecular mechanism in human placental iron transfer.
Aims
To investigate the iron dynamics in anemic and healthy pregnant women supplemented with daily and weekly IFA supplementation and its relation with clinical outcome.
Methods
The subjects include non-anemic primigravida (NAP) (Hemoglobin (Hb) > 11 g/ dl, N= 60) and anemic primigravida (AP) (8.0 < Hb < 11 g/ dl, N=60) were followed across pregnancy at three time-points i.e. baseline (13-16 weeks of gestation), after three months (25-28 weeks) and 6 weeks postpartum. The subjects (NAP and AP) were randomly allocated to daily dose comprised 100 mg iron and 500 μg folic acid tablets and weekly dose contained two IFA tablets/ week till six weeks postpartum. Corresponding changes in hematological markers, iron status indicators viz. ferritin, iron and soluble transferrin receptor (sTfR) in blood and placental ferritin expression was studied. Birth outcome, gestational length, infant weight and placental weight were recorded. The statistical significance level (p <0.05) between the groups were assessed by applying unpaired t-test using SPSS (version 20.0).
Results
Weekly IFA supplementation for three months has significantly altered the Hb, hematocrit and red blood cell (RBC) count (p<0.05) and increased the level of serum sTfR (p<0.002) at postpartum in AP. After three months of supplementation, serum iron and sTfR were significantly different (p<0.01) between the two supplemental groups in NAP; whereas, serum ferritin (p<0.001) was significantly high at postpartum in daily IFA group of NAP. Placental ferritin expression was increased in NAP supplemented with daily IFA in comparison to weekly IFA. The placentas obtained from AP supplemented with weekly IFA showed significantly low ferritin (p<0.05) expression when compared with daily IFA supplementation. However, birth outcome, infant weight, gestational length and placental weight were comparable in both the supplementation groups.
Conclusion
The placental ferritin expression and its serum level showed similar trend among anemic and non-anemic primigravidas supplemented with daily and weekly IFA tablets. Although, significantly lower placental ferritin was observed in AP supplemented with weekly IFA tablets; but there was not any difference in birth outcome, infant weight or gestational length between two supplementation groups. The modulation in iron transporter expression may be involved in anemic placentas to flux iron for developing fetus, thereby maintaining the healthy pregnancy. The results of this study revealed that blood iron status/ hematological markers may be helpful to assess the optimum amount of supplemental iron required during pregnancy.
Session topic: E-poster
Keyword(s): Iron deficiency anemia, Iron transport, Pregnancy
Abstract: PB2131
Type: Publication Only
Background
Iron deficiency (ID) globally impact billions of people; mostly pregnant women. Anemia during pregnancy is mainly associated with ID; and prophylaxis includes daily supplementation of iron folic acid (IFA) tablets. During pregnancy, increased foetal iron demand leads to fluctuations in body iron reserves; thus supplemental iron is recommended to meet the iron demand. The effectiveness of weekly IFA supplementation in comparison to daily IFA intake during pregnancy is still shadowy, as the available data from well-defined clinical trials is inconsistent. The amount of quantifiable iron circulating in blood and stored in placenta, in both the supplementation schemes and their correlation with pregnancy outcomes is pre-requisite to reach any firm conclusion. Owing to this, the present study was conducted to providing better understanding of hemodynamics and molecular mechanism in human placental iron transfer.
Aims
To investigate the iron dynamics in anemic and healthy pregnant women supplemented with daily and weekly IFA supplementation and its relation with clinical outcome.
Methods
The subjects include non-anemic primigravida (NAP) (Hemoglobin (Hb) > 11 g/ dl, N= 60) and anemic primigravida (AP) (8.0 < Hb < 11 g/ dl, N=60) were followed across pregnancy at three time-points i.e. baseline (13-16 weeks of gestation), after three months (25-28 weeks) and 6 weeks postpartum. The subjects (NAP and AP) were randomly allocated to daily dose comprised 100 mg iron and 500 μg folic acid tablets and weekly dose contained two IFA tablets/ week till six weeks postpartum. Corresponding changes in hematological markers, iron status indicators viz. ferritin, iron and soluble transferrin receptor (sTfR) in blood and placental ferritin expression was studied. Birth outcome, gestational length, infant weight and placental weight were recorded. The statistical significance level (p <0.05) between the groups were assessed by applying unpaired t-test using SPSS (version 20.0).
Results
Weekly IFA supplementation for three months has significantly altered the Hb, hematocrit and red blood cell (RBC) count (p<0.05) and increased the level of serum sTfR (p<0.002) at postpartum in AP. After three months of supplementation, serum iron and sTfR were significantly different (p<0.01) between the two supplemental groups in NAP; whereas, serum ferritin (p<0.001) was significantly high at postpartum in daily IFA group of NAP. Placental ferritin expression was increased in NAP supplemented with daily IFA in comparison to weekly IFA. The placentas obtained from AP supplemented with weekly IFA showed significantly low ferritin (p<0.05) expression when compared with daily IFA supplementation. However, birth outcome, infant weight, gestational length and placental weight were comparable in both the supplementation groups.
Conclusion
The placental ferritin expression and its serum level showed similar trend among anemic and non-anemic primigravidas supplemented with daily and weekly IFA tablets. Although, significantly lower placental ferritin was observed in AP supplemented with weekly IFA tablets; but there was not any difference in birth outcome, infant weight or gestational length between two supplementation groups. The modulation in iron transporter expression may be involved in anemic placentas to flux iron for developing fetus, thereby maintaining the healthy pregnancy. The results of this study revealed that blood iron status/ hematological markers may be helpful to assess the optimum amount of supplemental iron required during pregnancy.
Session topic: E-poster
Keyword(s): Iron deficiency anemia, Iron transport, Pregnancy
Type: Publication Only
Background
Iron deficiency (ID) globally impact billions of people; mostly pregnant women. Anemia during pregnancy is mainly associated with ID; and prophylaxis includes daily supplementation of iron folic acid (IFA) tablets. During pregnancy, increased foetal iron demand leads to fluctuations in body iron reserves; thus supplemental iron is recommended to meet the iron demand. The effectiveness of weekly IFA supplementation in comparison to daily IFA intake during pregnancy is still shadowy, as the available data from well-defined clinical trials is inconsistent. The amount of quantifiable iron circulating in blood and stored in placenta, in both the supplementation schemes and their correlation with pregnancy outcomes is pre-requisite to reach any firm conclusion. Owing to this, the present study was conducted to providing better understanding of hemodynamics and molecular mechanism in human placental iron transfer.
Aims
To investigate the iron dynamics in anemic and healthy pregnant women supplemented with daily and weekly IFA supplementation and its relation with clinical outcome.
Methods
The subjects include non-anemic primigravida (NAP) (Hemoglobin (Hb) > 11 g/ dl, N= 60) and anemic primigravida (AP) (8.0 < Hb < 11 g/ dl, N=60) were followed across pregnancy at three time-points i.e. baseline (13-16 weeks of gestation), after three months (25-28 weeks) and 6 weeks postpartum. The subjects (NAP and AP) were randomly allocated to daily dose comprised 100 mg iron and 500 μg folic acid tablets and weekly dose contained two IFA tablets/ week till six weeks postpartum. Corresponding changes in hematological markers, iron status indicators viz. ferritin, iron and soluble transferrin receptor (sTfR) in blood and placental ferritin expression was studied. Birth outcome, gestational length, infant weight and placental weight were recorded. The statistical significance level (p <0.05) between the groups were assessed by applying unpaired t-test using SPSS (version 20.0).
Results
Weekly IFA supplementation for three months has significantly altered the Hb, hematocrit and red blood cell (RBC) count (p<0.05) and increased the level of serum sTfR (p<0.002) at postpartum in AP. After three months of supplementation, serum iron and sTfR were significantly different (p<0.01) between the two supplemental groups in NAP; whereas, serum ferritin (p<0.001) was significantly high at postpartum in daily IFA group of NAP. Placental ferritin expression was increased in NAP supplemented with daily IFA in comparison to weekly IFA. The placentas obtained from AP supplemented with weekly IFA showed significantly low ferritin (p<0.05) expression when compared with daily IFA supplementation. However, birth outcome, infant weight, gestational length and placental weight were comparable in both the supplementation groups.
Conclusion
The placental ferritin expression and its serum level showed similar trend among anemic and non-anemic primigravidas supplemented with daily and weekly IFA tablets. Although, significantly lower placental ferritin was observed in AP supplemented with weekly IFA tablets; but there was not any difference in birth outcome, infant weight or gestational length between two supplementation groups. The modulation in iron transporter expression may be involved in anemic placentas to flux iron for developing fetus, thereby maintaining the healthy pregnancy. The results of this study revealed that blood iron status/ hematological markers may be helpful to assess the optimum amount of supplemental iron required during pregnancy.
Session topic: E-poster
Keyword(s): Iron deficiency anemia, Iron transport, Pregnancy
{{ help_message }}
{{filter}}